评估高剂量达普托米辛在患有甲素耐药黄金葡萄球菌病的儿童中的使用:一系列病例
Katie B Olney1,2, Manjunath P Pai3, Laura P Stadler4
1From the Department of Pharmacy, University of Kentucky HealthCare.
The Pediatric infectious disease journal
|May 29, 2025
概括
儿科达普托米辛的剂量需要更新. 目前的高剂量在儿童中产生的药物暴露量低于预期,这表明需要修订儿童用药剂量建议,以治疗黄金葡萄球菌感染.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 儿童传染病 儿童传染病
背景情况:
- 目前的儿科达普托米辛剂量尚未更新,以反映成人推.
- 在儿科患者中观察到低于最佳的药物暴露.
研究的目的:
- 评估在接受高剂量的儿科患者中达普托米辛的暴露.
- 突出需要修订儿科剂量指南的需要.
主要方法:
- 对儿科患者的达普托米辛剂量和药理动力学数据的回顾性分析.
- 计算曲线下的24小时面积 (AUC),以评估药物暴露.
主要成果:
- 在4名儿童中,24小时AUC的中位数为378 mg·h/L (IQR:368-413).
- 观察到的药物暴露量低于预期,尽管达普托米辛剂量高 (17-20 mg/kg/d).
结论:
- 当代儿科达普托米辛剂量可能导致药物暴露不足.
- 对儿科患者的达普托米辛剂量方案的重新评估对于治疗金黄色葡萄球菌感染至关重要.
更多相关视频
相关概念视频
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
238
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
238
Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Drug Dosing: Infants and Children
257
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
257
Acute Pyelonephritis II: Diagnostic Studies and Management
323
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
323
Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
249
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
249


